What is the standard of care for locally advanced Ovarian Cancer according to NCCN guidelines

Standard of Care for Locally Advanced Ovarian Cancer (NCCN Guidelines)

Based on the NCCN Guidelines Version 3.2025 for Ovarian Cancer, here's what constitutes standard care for locally advanced disease (Stage III):

PRIMARY TREATMENT APPROACH

For patients with Stage III ovarian cancer, the standard of care involves a two-pronged approach:

1. Surgical Debulking (Cytoreduction)

According to NCCN Guidelines, a gynecologic oncologist should perform the primary surgery—this is a Category 1 recommendation based on high-level evidence showing improved survival outcomes.

The surgical goal is optimal cytoreduction, which typically includes:

• Hysterectomy (removal of uterus)
• Bilateral salpingo-oophorectomy (BSO—removal of both ovaries and fallopian tubes)
• Omentectomy (removal of omentum, a tissue in the abdomen)
• Lymphadenectomy (removal of suspicious/enlarged lymph nodes)
• Additional procedures as needed (bowel resection, diaphragm stripping, etc.)

Important note: For Stage III patients with low-volume residual disease after debulking, placement of an intraperitoneal (IP) catheter should be considered during initial surgery, as this enables IP chemotherapy delivery.

2. Systemic Chemotherapy

Most Stage III patients receive platinum-based chemotherapy after surgery. The NCCN Guidelines recommend:

Chemotherapy options include:

• IV (intravenous) platinum-based regimens, OR
• IV/IP (intravenous plus intraperitoneal) combined chemotherapy

For optimally debulked Stage III cancer, the IP regimen has demonstrated impressive results:

• Median overall survival: 65.6 months
• For patients receiving dose-dense weekly paclitaxel/carboplatin: median OS of 100.5 months

NEOADJUVANT THERAPY (NACT) ALTERNATIVE

For patients who are NOT good surgical candidates due to:

• Advanced age
• Frailty or poor performance status
• Significant comorbidities
• Disease unlikely to be optimally cytoreduced

NACT (neoadjuvant chemotherapy) with interval debulking surgery (IDS) is a Category 1 recommendation. This approach:

• Gives chemotherapy FIRST to shrink the tumor
• Allows medical improvement of the patient
• Increases likelihood of optimal cytoreduction at a later surgery
• Is followed by additional chemotherapy

MAINTENANCE THERAPY

After first-line platinum-based chemotherapy, PARP inhibitors have been incorporated as NCCN-recommended maintenance therapy options for select Stage III patients, particularly those with:

• BRCA1/2 mutations
• Homologous recombination deficiency (HRD) status

MOLECULAR TESTING REQUIREMENTS

Before treatment decisions, NCCN Guidelines recommend validated tumor molecular testing in a CLIA-approved facility, including:

• BRCA1/2 status (germline and somatic)
• HRD (homologous recombination deficiency) status
• Additional markers: HER2, MSI, MMR, TMB, BRAF, FRα (FOLR1), RET, NTRK

This testing informs which maintenance therapy options may provide the most benefit.

SUPPORTIVE CARE

Throughout treatment, NCCN Guidelines emphasize:

• Symptom management and best supportive care
• Referral for palliative care assessment as appropriate
• Long-term wellness care and survivorship planning
• Patient education about signs of recurrence (pelvic pain, bloating, early satiety, weight loss, fatigue)

KEY TAKEAWAY

The standard of care for Stage III ovarian cancer prioritizes optimal surgical debulking by a gynecologic oncologist followed by platinum-based chemotherapy, with consideration of IP chemotherapy delivery and subsequent maintenance therapy based on molecular testing results.

---

Sources cited:

• NCCN Guidelines Version 3.2025: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer – Specifically addressing primary treatment, surgical principles, systemic therapy, and maintenance therapy recommendations for Stage III disease

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.